CANNABIS PRODUCTS

articles with this tag

What’s Happening to the CPH Share Price?

What’s Happening to the CPH Share Price?

Over recent days, Creso Pharma (ASX: CPH) appears to have gained some significant momentum. Momentum includes three new purchase orders for Creso Pharma’s anibidiol® line of animal health products were signed today, to a value of $A$414,000.

Canopy Growth Founder Joins a Refreshed, Re-Set and Re-Funded CPH

Canopy Growth Founder Joins a Refreshed, Re-Set and Re-Funded CPH

While Creso Pharma (ASX: CPH) continues to sign purchase orders and has appointed Bruce Linton as an advisor, it is a highly speculative investment, and our intent is to hold for the coming months through to Christmas to see how the company’s strategy plays out.

Creso’s New Immunity Boosting CBD Hemp Teas Set for Release

Creso’s New Immunity Boosting CBD Hemp Teas Set for Release

Creso Pharma Limited (ASX: CPH) is expanding its available product line with the release of a hemp tea in Q3 2020.

CPH Secures Two Execs from the World’s Largest Cannabis Company

CPH Secures Two Execs from the World’s Largest Cannabis Company

ASX Junior Creso Pharma (ASX: CPH) has appointed two former Canopy executives to the senior management team of its wholly-owned Mernova Medical Inc. in Nova Scotia, Canada.

Scandinavian Sales Agreement Expands Creso Pharma’s European Footprint

Scandinavian Sales Agreement Expands Creso Pharma’s European Footprint

Creso Pharma Limited (ASX:CPH, FRA:1X8) has signed a commercial term sheet agreement with Farmagon, Oslo, Norway to enter the Scandinavia market with Creso products.

Creso on a Roll: New Hemp Plant Product for Equines and Large Animals Set for Release

Creso on a Roll: New Hemp Plant Product for Equines and Large Animals Set for Release

Creso Pharma (ASX:CPH) today announced the successful development of anibidiol®EQUI, a flavoured micromilled hemp plant product for equines and large animals.

CPH Set to Expand cannaQIX® Product Line After Major Technological Breakthrough

CPH Set to Expand cannaQIX® Product Line After Major Technological Breakthrough

Hot on the heels of major developments in human and animal health, Creso Pharma (ASX:CPH) has achieved another key milestone: a technological breakthrough that will expand its cannaQIX® human health product line,

CPH’s cannaQIX® Products Have Now Exceeded the 2.5 million Lozenges Sold Milestone

CPH’s cannaQIX® Products Have Now Exceeded the 2.5 million Lozenges Sold Milestone

Creso Pharma (ASX:CPH, FRA:1X8) has announced its second major milestone for the year. Today is has informed the market that its flagship cannaQIX® line surpassed the milestone of 100,000 packs sold. The 100,000 pack milestone corresponds to over 2.5 million cannaQIX® lozenges sold since the product’s launch in April 2018.

CPH Delivers Over 3 Million Anibidiol Doses to Europe's Dogs

CPH Delivers Over 3 Million Anibidiol Doses to Europe's Dogs

Momentum has been building over the last couple of months as CresoPharma (ASX:CPH) outlined its strategy for generating substantial growth in 2020.

CPH Kick Start African Launch - $300k Order Values Confirmed

CPH Kick Start African Launch - $300k Order Values Confirmed

Creso Pharma (ASX:CPH | FRA:1X8) has announced that through Pharma Dynamics, Creso’s partner in the African region, initial orders worth approximately A$300,000 for the cannaQIX® product range have been made.

Can New Cannabis Products Launch Creso Pharma Higher in 2020?

Can New Cannabis Products Launch Creso Pharma Higher in 2020?

Through partnerships with leading global companies, Creso Pharma (ASX:CPH) has been able to, and will continue to accelerate the development and distribution of its products worldwide.

Game Changer? ASX Stock Reverse Engineering Cannabis Plants

Game Changer? ASX Stock Reverse Engineering Cannabis Plants

Who is the ASX company with transforming qualities that could completely disrupt the cannabis and CBD markets?

Thanks for subscribing!

X